1. Safety and Immunogenicity of 3 Doses of BNT162b2 and CoronaVac in Children and Adults with Inborn Errors of Immunity
- Author
-
Daniel Leung, Xiaofeng Mu, Jaime Rosa Duque, Samuel Cheng MS, Manni Wang, Wenyue Zhang, Yanmei Zhang, Issan Tam YS, Toby Lee SS, Jennifer Lam HY, Sau Man Chan, Cheuk Hei Cheang, Yuet Chung, Howard Wong HW, Amos Lee MT, Wing Yan Li, Sara Chaothai, Leo Tsang CH, Gilbert T Chua, Kai-Ning Cheong, Elaine Au, Janette Kwok SY, Koon Wing Chan, Patrick Chong, Pamela Lee, Marco HK Ho, Tsz Leung Lee, Tu WW, Malik Peiris, and YL Lau
- Subjects
Adult ,Vaccines, Synthetic ,COVID-19 Vaccines ,SARS-CoV-2 ,Immunology ,COVID-19 ,Antibodies, Viral ,Vaccines, Inactivated ,Child, Preschool ,Immunoglobulin G ,Cytokines ,Humans ,Immunology and Allergy ,mRNA Vaccines ,Child ,BNT162 Vaccine - Abstract
Background Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in adult and pediatric patients with inborn errors of immunity (IEIs) remain unknown. Intradermal vaccination may improve immunogenicity in immunocompromised patients. Our study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT162b2 (age 12+) or inactivated whole-virion vaccine CoronaVac (age 3+) in Hong Kong, including Omicron BA.1 neutralization, in a nonrandomized manner. Intradermal vaccination was also studied. Methods Thirty-nine patients were vaccinated, including 16 with homologous intramuscular 0.3ml BNT162b2 and 17 with homologous intramuscular 0.5ml CoronaVac. Two patients received 3 doses of intradermal 0.5ml CoronaVac, and 4 patients received 2 doses of intramuscular BNT162b2 and the third dose with intradermal BNT162b2. Adverse reactions and adverse events were tracked for 7 and 28 days after each dose. Antibody responses assessed included binding IgG antibody to wild-type (WT) spike receptor-binding domain (S-RBD IgG) and surrogate neutralization activity to WT and BA.1 viruses. T cell responses were examined by intracellular cytokine staining following stimulation with SARS-CoV-2 peptide pool(s). Results No safety concerns were identified. Inadequate antibody responses were found after 2 doses in patients with humoral immunodeficiencies and especially so against BA.1. Dose 3 of either vaccine increased S-RBD IgG response. T cell responses against SARS-CoV-2 antigens were detected in vaccinated IEI patients. Intradermal third dose vaccine led to high antibody response in 4 patients. Conclusions The primary vaccination series of BNT162b2 and CoronaVac in adults and children with IEIs should include 3 doses for optimal immunogenicity.
- Published
- 2022
- Full Text
- View/download PDF